Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services




Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services

NEWTOWN, Pa., Oct. 23, 2025 (GLOBE NEWSWIRE) — Solana Company (NASDAQ: HSDT or the “Company”) announced that it has entered into agreements with Helius and Twinstake (each, a “Provider,” and collectively, the “Providers”), related to non-custodial staking services. The Company is also staking its SOL holdings directly from qualified custody at Anchorage Digital Bank.

The Providers have developed non-custodial staking and restaking solutions that allow users to delegate, stake, and/or restake their digital assets to earn rewards. Pursuant to the agreements, the Providers will make their platforms available to the Company and provide the Company with certain services, which include staking, voting with staked tokens, and reporting with regard to the staked tokens.

“This marks an important next step in executing our digital asset treasury strategy,” said Joseph Chee, Executive Chairman of HSDT and Chairman of Summer Capital. “By staking with industry leaders like Helius and Twinstake, we are strengthening the operational backbone of our SOL holdings while contributing to the resilience and decentralization of the Solana ecosystem. Both providers rank among the top 25 validators on the Solana network by total SOL staked, signaling their established track record and strong confidence within the community.”

Cosmo Jiang, General Partner at Pantera Capital and Board Observer at HSDT, added: “These partnerships position HSDT to maximize on-chain yield in a secure, compliant and scalable manner. Partnering with top-tier validators trusted by the broader Solana community reinforces our focus on institutional-grade execution and network alignment. As Solana continues to lead in performance and adoption, we see staking as both a core part of our return generation strategy and a reinforcement of our commitment to the network’s long-term growth.”

Helius, the leading Solana validator with over 13 million SOL staked, offers institutional-grade staking services and operates SOC 2 Type II-compliant infrastructure, ensuring optimal uptime, performance and security. Twinstake and Anchorage Digital bring complementary strengths in regulated and enterprise-level staking, expanding the Company’s exposure to the broader Solana validator ecosystem.

“Crypto is connecting the internet of value,” said Mert Mumtaz, Co-founder and CEO of Helius. “Solana today is the only blockchain network with the scale to onboard all of the world’s capital markets, microtransactions, and AI payments. Together with the Solana Company, we’re accelerating institutional adoption of Solana, and building the future of the world’s trading terminal.”

Solana has historically been the fastest-growing blockchain, leading the industry in transaction revenue, and processing more than 3,500 transactions per second. The network is also the most widely adopted, with an average of around 3.7 million daily active wallets and surpassing 23 billion transactions year-to-date. SOL is financially productive by design, offering a ~7% native staking yield, whereas assets like BTC are non-yield-bearing.

As an independent treasury company, HSDT’s mission is to support the growth and security of tokenized networks by serving as a long-term holder of $SOL, in addition to continuing the development of its neurotech and medical device operations.

Forward Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. This press release also includes express and implied forward-looking statements regarding the Company’s current expectations, estimates, opinions and beliefs that are not historical facts. Such forward-looking statements may be identified by words such as “believes,” “expects,” “endeavors,” “anticipates,” “intends,” “plans,” “estimates,” “projects,” “should” and “objective” and the negative and variations of such words and similar words. These statements are made on the basis of current knowledge and, by their nature, involve numerous assumptions and uncertainties. Nothing set forth herein should be regarded as a representation, warranty or prediction that we will achieve or are likely to achieve any particular future result. Actual results may differ materially from those indicated in the forward-looking statements because the realization of those results is subject to many risks and uncertainties, including the risk that we may fail to realize the anticipated benefits of the private placement, including the ability of the Company to execute on its digital asset treasury strategy, as well as risks related to economic conditions, fluctuations in the market price of SOL, and the evolving regulatory environment, as well as other factors. Forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no duty to update such information except as required under applicable law.

About Solana Company

Solana Company (NASDAQ: HSDT) is a listed digital asset treasury dedicated to acquiring Solana (SOL), created in partnership with Pantera and Summer Capital. Focused on maximizing SOL per share by leveraging capital markets opportunities and onchain activity, Solana Company offers public market investors optimal exposure to Solana’s secular growth. https://www.solanacompany.co/

For additional information, follow us on:

https://x.com/Solana_Company
https://www.linkedin.com/company/helius-solana-company/

Synfini Selected for SLAS 2026 Innovation AveNEW Showcase




Synfini Selected for SLAS 2026 Innovation AveNEW Showcase

Company Selected to Demonstrate its Novel AI Foundry That Unites Virtual and Physical Chemistry, Reducing the Time and Cost of Modern Molecular Discovery

MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Synfini, Inc., provider of the industry’s most innovative Agile AI Foundry for drug discovery, today announced it has been chosen for the prestigious Innovation AveNEW showcase at the Society for Laboratory Automation and Screening (SLAS) 2026 International Conference and Exhibition.

Hosted annually by SLAS, the Innovation AveNEW program spotlights early-stage companies with breakthrough technologies that advance laboratory automation, screening, and life sciences research. Selected companies are invited to exhibit at the SLAS 2026 International Conference and Exhibition, which will be held February 7-11, 2026, in Boston, MA. The conference is attended by more than 7,000 scientists, engineers, entrepreneurs, and technology providers shaping the future of life sciences automation.

As an Innovation AveNEW participant, Synfini will demonstrate its unique platform at Booth 1463-N during SLAS 2026. The company will highlight how the Synfini Platform raises small molecule chemistry lab automation to a new level by embracing and extending existing AI designs with novel AI methods. It advances AI molecule designs to physical experiments, with more than 1,500 validated, multistep automated protocols. It enables chemists to execute these protocols in a Cloud Foundry model, which requires no CapEx investment by its users. Since its spinout from SRI in 2023, Synfini has validated its approach through commercial traction and strategic partnerships.

“Being selected for Innovation AveNEW is a tremendous honor,” said Doug Donzelli, CEO of Synfini. “It reflects our team’s commitment to advancing scientific discovery through intelligent automation and collaboration with the global life sciences community.” 

With this recognition, Synfini has also been invited to compete for the SLAS Ignite Award, which recognizes companies demonstrating the strongest potential for impact, growth, and scientific innovation.

Attendees are invited to contact Synfini to learn more or arrange a conference briefing.

About Synfini: 

The Synfini AI Cloud Foundry uniquely offers rapid, cost-effective access to cutting-edge, small-molecule optimization technologies. Designed to support researchers and drug hunters, Synfini simplifies the journey from target discovery to optimized drug candidates. The Synfini platform aims to accelerate the development of important new therapies and improve patients’ lives. Synfini is located in Menlo Park, California. Learn more at www.synfini.com  

About SLAS: 
The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation technology and tools. SLAS leads the pursuit of research excellence by offering tangible resources such as its international conferences and symposia, scientific publishing, and opportunities for continuing education, grants and scholarships, professional collaboration, networking, and career advancement. 

Contact: 
media@ktcmarketingandpr.com

Synfini Selected for SLAS 2026 Innovation AveNEW Showcase




Synfini Selected for SLAS 2026 Innovation AveNEW Showcase

Company Selected to Demonstrate its Novel AI Foundry That Unites Virtual and Physical Chemistry, Reducing the Time and Cost of Modern Molecular Discovery

MENLO PARK, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Synfini, Inc., provider of the industry’s most innovative Agile AI Foundry for drug discovery, today announced it has been chosen for the prestigious Innovation AveNEW showcase at the Society for Laboratory Automation and Screening (SLAS) 2026 International Conference and Exhibition.

Hosted annually by SLAS, the Innovation AveNEW program spotlights early-stage companies with breakthrough technologies that advance laboratory automation, screening, and life sciences research. Selected companies are invited to exhibit at the SLAS 2026 International Conference and Exhibition, which will be held February 7-11, 2026, in Boston, MA. The conference is attended by more than 7,000 scientists, engineers, entrepreneurs, and technology providers shaping the future of life sciences automation.

As an Innovation AveNEW participant, Synfini will demonstrate its unique platform at Booth 1463-N during SLAS 2026. The company will highlight how the Synfini Platform raises small molecule chemistry lab automation to a new level by embracing and extending existing AI designs with novel AI methods. It advances AI molecule designs to physical experiments, with more than 1,500 validated, multistep automated protocols. It enables chemists to execute these protocols in a Cloud Foundry model, which requires no CapEx investment by its users. Since its spinout from SRI in 2023, Synfini has validated its approach through commercial traction and strategic partnerships.

“Being selected for Innovation AveNEW is a tremendous honor,” said Doug Donzelli, CEO of Synfini. “It reflects our team’s commitment to advancing scientific discovery through intelligent automation and collaboration with the global life sciences community.” 

With this recognition, Synfini has also been invited to compete for the SLAS Ignite Award, which recognizes companies demonstrating the strongest potential for impact, growth, and scientific innovation.

Attendees are invited to contact Synfini to learn more or arrange a conference briefing.

About Synfini: 

The Synfini AI Cloud Foundry uniquely offers rapid, cost-effective access to cutting-edge, small-molecule optimization technologies. Designed to support researchers and drug hunters, Synfini simplifies the journey from target discovery to optimized drug candidates. The Synfini platform aims to accelerate the development of important new therapies and improve patients’ lives. Synfini is located in Menlo Park, California. Learn more at www.synfini.com  

About SLAS: 
The Society for Laboratory Automation and Screening (SLAS) is an international professional society of academic, industry and government researchers as well as developers and providers of laboratory automation technology and tools. SLAS leads the pursuit of research excellence by offering tangible resources such as its international conferences and symposia, scientific publishing, and opportunities for continuing education, grants and scholarships, professional collaboration, networking, and career advancement. 

Contact: 
media@ktcmarketingandpr.com

Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide




Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide

The health tech company adds more than 1,700 Albertsons Cos. pharmacies to its partnership base of over 37,000 locations

ESTERO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) — Visory Health, a patient-first health tech prescription platform that is transforming the way veterans, families and caregivers access affordable healthcare through its prescription discount card, today announced a new collaboration with Albertsons^® Companies, Inc., a leading food and drug retailer in the United States. This collaboration expands Visory Health’s growing network of retail and pharmacy partners, which already includes Kroger, Food Lion and others.

As healthcare and living costs continue to rise, millions of Americans face challenges affording essential medications in addition to necessary expenses like groceries. More than 9 million Americans reported skipping their medication doses to save on costs, according to a 2023 CDC report. The new partnership between Visory Health and Albertsons Cos. aims to address this issue by making prescription medications more affordable and accessible.

“In addition to the rising costs of healthcare, millions of Americans face challenges accessing necessary medications due to factors like distance and affordability,” said Alexandra Robertson, SVP of Growth at Visory Health. “By expanding into Albertsons Cos. pharmacies, we’re helping more people access affordable prescriptions closer to home, bringing added convenience and value to customers.”

Albertsons Cos. pharmacies offer a wide range of services including vaccinations, health screenings and prescription management. Through this partnership, customers can present their Visory Health discount card at participating Albertsons Cos. pharmacy locations, including Albertsons, Safeway, ACME, Randalls, Tom Thumb, Shaw’s, Jewel-Osco and Amigos to save up to 80% off medications.

Customers can download the Visory Health app from the App Store or Google Play Store to access their digital discount card. A Visory card is also available for download on the “Rx Savings Card” page on Visory Health’s website.

About Visory Health

Visory Health is a patient-first health tech platform transforming how everyone, including Veterans, families, caregivers and underserved individuals, have access to healthcare. Visory Health’s model puts customer’s needs at the core of how it operates. They have saved millions of customers money on prescription medications, creating healthier families and communities. With a network of over 37,000 pharmacy partners nationwide including Walgreens, Kroger, Publix, Stop & Shop and more, Visory Health delivers affordable prescription prices nationwide and is free to use. To learn more, visit www.visoryhealth.com.

Media Contact

Erica Torres

Uproar by Moburst for Visory Health

erica.torres@moburst.com

Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide




Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide

The health tech company adds more than 1,700 Albertsons Cos. pharmacies to its partnership base of over 37,000 locations

ESTERO, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) — Visory Health, a patient-first health tech prescription platform that is transforming the way veterans, families and caregivers access affordable healthcare through its prescription discount card, today announced a new collaboration with Albertsons^® Companies, Inc., a leading food and drug retailer in the United States. This collaboration expands Visory Health’s growing network of retail and pharmacy partners, which already includes Kroger, Food Lion and others.

As healthcare and living costs continue to rise, millions of Americans face challenges affording essential medications in addition to necessary expenses like groceries. More than 9 million Americans reported skipping their medication doses to save on costs, according to a 2023 CDC report. The new partnership between Visory Health and Albertsons Cos. aims to address this issue by making prescription medications more affordable and accessible.

“In addition to the rising costs of healthcare, millions of Americans face challenges accessing necessary medications due to factors like distance and affordability,” said Alexandra Robertson, SVP of Growth at Visory Health. “By expanding into Albertsons Cos. pharmacies, we’re helping more people access affordable prescriptions closer to home, bringing added convenience and value to customers.”

Albertsons Cos. pharmacies offer a wide range of services including vaccinations, health screenings and prescription management. Through this partnership, customers can present their Visory Health discount card at participating Albertsons Cos. pharmacy locations, including Albertsons, Safeway, ACME, Randalls, Tom Thumb, Shaw’s, Jewel-Osco and Amigos to save up to 80% off medications.

Customers can download the Visory Health app from the App Store or Google Play Store to access their digital discount card. A Visory card is also available for download on the “Rx Savings Card” page on Visory Health’s website.

About Visory Health

Visory Health is a patient-first health tech platform transforming how everyone, including Veterans, families, caregivers and underserved individuals, have access to healthcare. Visory Health’s model puts customer’s needs at the core of how it operates. They have saved millions of customers money on prescription medications, creating healthier families and communities. With a network of over 37,000 pharmacy partners nationwide including Walgreens, Kroger, Publix, Stop & Shop and more, Visory Health delivers affordable prescription prices nationwide and is free to use. To learn more, visit www.visoryhealth.com.

Media Contact

Erica Torres

Uproar by Moburst for Visory Health

erica.torres@moburst.com

Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform




Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform

Collaboration with Monash University to Address a Large Pharmaceutical Opportunity

MELBOURNE, Australia, Oct. 23, 2025 (GLOBE NEWSWIRE) — Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced it has started a preclinical animal trial evaluating its proprietary formulation technology for oily and poorly soluble drugs. Gelteq will conduct the study with Monash University Institute of Pharmaceutical Science, a recognised leader in pharmaceutical development and contract research.

“Effective oral delivery of oily and poorly soluble drugs represents one of the biggest challenges in drug development and commercialisation,” said Nathan Givoni, CEO of Gelteq. “More than 40% of marketed drugs and up to 90% of discovery candidates suffer from low solubility and variable bioavailability, leading to higher dosing, greater side effect risk, and inconsistent patient outcomes. By leveraging Gelteq’s formulation expertise, we aim to unlock the full potential of oily and poorly soluble drugs, revive shelved molecules and create new value for global pharmaceutical partners.”

Pharmaceutical companies invest more than USD $4 billion annually in technologies to improve delivery of oily and poorly soluble drugs (1), including solubility-enhancement excipients, lipid-based formulations and lipid nanoparticles with strong projected growth through 2030 (1,2,3). However, there are increasing concerns that emulsifiers in lipid-based drug delivery can disrupt the gut microbiota and compromise gastrointestinal health so it is important to reduce reliance on such additives to enable safer and more effective delivery of oily or poorly soluble drugs (4).

Should Gelteq be able to demonstrate through the trial its ability to work successfully with oily or poorly soluble drugs, Gelteq would seek to assist potential clients with a portfolio of oily and poorly soluble drugs via the following commercial options:

• Pipeline salvage – reviving promising drug molecules previously abandoned due to solubility and bioavailability issues.
• Lifecycle extension – reformulating existing drugs to provide new patent protection and exclusivity.
• Improved adherence – the potential to reduce API dose size and food-effect dependence, which has the potential for fewer side effects and more consistent patient outcomes.

“This preclinical trial represents an important step to demonstrate Gelteq’s ability to transform a major and unmet need across the pharmaceutical industry,” added Mr. Givoni.

About Gelteq Ltd.

Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit www.gelteq.com.

Gelteq Contact:
Investor Relations
Matt Kreps, Darrow Associates IR
+1-214-597-8200
mkreps@darrowir.com

Forward-Looking Statements

Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

References

1. 360iResearch. (2024). Solubility enhancement excipients market: Global forecast 2025–2032 (Report ID: 5675273). Research and Markets.
2. Allied Market Research. (2025). Targeted liposomes drug delivery market: Global opportunity analysis and industry forecast, 2023–2032 (Report ID: A12661).
3. Grand View Research. (2025). Lipid nanoparticle market, 2025–2030 (Report ID: GVR-4-68040-547-5).
4. Subramaniam, S., Elz, A., Wignall, A., Kamath, S., Ariaee, A., Hunter, A., et al. (2023). Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats. International Journal of Pharmaceutics, 648, 123614.

Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors




Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors

— First-in-class non-oncolytic arenavirus-based approach designed to induce targeted, effective, and durable anti-cancer activity against primary tumors and metastases –

— Phase 1 study to evaluate the safety and tolerability of ABX-001 and determine the recommended Phase 2 dose in patients with refractory/relapsed solid tumors —

Düsseldorf, Germany, October 23, 2025 – Abalos Therapeutics announced today that the first patient has been dosed in the first-in-human study in patients with advanced solid tumors who have exhausted standard of care. The trial is evaluating ABX-001, the company’s lead non-lytic viroimmunotherapy candidate, designed to systemically activate strong innate (immediate) and adaptive (memory) immune responses against cancer cells and actively guide immune cells into the tumor. In preclinical models, ABX-001 showed increased tumor T cell infiltration and T cell-mediated anti-tumor activity, while maintaining a favorable safety profile.

“Transitioning into a clinical-stage company is a strong validation of Abalos’ scientific approach and team and advances our mission to overcome current limitations in immunotherapy for a broad cancer patient population,” commented Gerben Moolhuizen, CEO at Abalos. “We believe that ABX-001 offers unique immunostimulatory and anti-tumoral properties, enabled by persistent and sustained replication of ABX-001 in cancerous and antigen-presenting cells, without destroying them. With this novel approach, we aim to safely engage all key immune organs in a concerted attack against a patient’s tumor, including migrating and metastasized cancer cells. This first-in-human trial will provide a critical foundation for ABX-001’s further clinical development. We are excited about the potential impact for patients and look forward to providing updates as the trial progresses.”

The Phase 1 clinical trial (EUCT 2024-512403-39-01) is a first-in-human, open-label, multicenter study to evaluate safety and tolerability, and determine the recommended Phase 2 dose (RP2D) of ABX-001, which is administered intravenously as monotherapy in approximately 18 patients with refractory/relapsed advanced solid tumors. Patients will receive a single intravenous administration of ABX-001 in a dose-escalation approach. In addition to safety and tolerability, early signs of efficacy will be assessed, defined by overall response (OR) based on RECIST 1.1 criteria and immune RECIST, as well as best percentage change from baseline in size of target lesions, up to 12 weeks from the start of treatment.

The clinical trial initiation follows the recent publication of preclinical proof-of-concept results for ABX-001 in Cell Reports Medicine. In various murine tumor in vivo models, ABX-001 achieved strong anti-tumoral efficacy by inducing the expansion of tumor-specific T cells and immune-activating cytokines, including type I interferons. Treatment of non-human primates (NHP) with ABX-001 led to substantially increased levels of immunostimulatory cytokines and chemokines, as well as significantly increased expansion of CD4+ and CD8+ T cells. Abalos’ lead candidate demonstrated a highly favorable safety profile, with minimal viral replication in healthy tissues and no severe disease symptoms in mice and NHPs highly susceptible to wild-type arenavirus.

About Abalos Therapeutics
Abalos Therapeutics is pioneering a novel anti-cancer approach that directs the full breadth of the immune system’s power specifically towards cancer cells. Abalos’ arenavirus-based drug candidates are designed to trigger precise innate and adaptive immune responses from within the tumor. They engage all relevant immune cell types in a concerted attack against both the primary tumor and distant metastases and actively guide them into the cancer tissue. Abalos’ lead product candidate ABX-001 has demonstrated strong anti-tumor efficacy in pre-clinical studies in multiple tumor models as well as an excellent pre-clinical safety profile and is now being evaluated in a Phase 1 trial in multiple solid tumors. Led by experienced biotech entrepreneurs and immunology pioneers, Abalos’ goal is to establish a new drug class in immuno-oncology. For more information, please visit www.abalos-tx.com.

For more information, please contact:

Abalos Therapeutics GmbH
Phone: +49 211 540104-0
Email: info@abalos-tx.com

Abalos media inquiries
Trophic Communications
Stephanie May / Marie-Theresa Weickert
Phone: +49 171 185 56 82
Email: abalos@trophic.eu

Attachment

• 20251023_Abalos_PR_FPI_ABX-001_Final

PCI Biotech update




PCI Biotech update

Oslo (Norway), 23 October 2025 – PCI Biotech (OSE: PCIB) today provides an update on the ongoing evaluation of its operations. 

Reference is made to the company’s announcements dated 18^th August 2025 and 25^th September 2025, as well as the interim report for the first half of 2025 published on 29^th August 2025. As previously communicated, current activities are focused on the evaluation of a new bioprocessing technology by an undisclosed party, conducted under a material transfer agreement without financial terms.

The company’s limited operations and the group’s future rely on continued interest under the ongoing technology evaluation. At present, there are no active discussions regarding strategic alternatives. The liquidity position of the PCI Biotech group is critical, and there can be no assurance that PCI Biotech will be able to secure financing. These material uncertainties cast significant doubt on the PCI Biotech group’s ability to continue as a going concern.

The management team has been restructured and now consists solely of the CEO position in the parent company, PCI Biotech Holding ASA. The wholly owned subsidiary, PCI Biotech AS, has opted not to have a CEO position. The board of directors of PCI Biotech Holding ASA will assume a similar role in the wholly owned subsidiary PCI Biotech AS.

Further information and updates will be provided when applicable.

For further information, please contact:
Ronny Skuggedal, CEO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech        
PCI Biotech is a biopharmaceutical company focusing on developing and commercialising new technologies and novel therapies through its photochemical technology platform originating from world-leading research at the Oslo University Hospital. The technology platform was until August 2025 under development in two different areas. (1) Photochemical lysis (PCL), inducing selective light-triggered cell lysis, which may enhance yield and purity in viral vector manufacturing. (2) Photochemical internalisation (PCI), inducing light-triggered endosomal release, which may unlock the potential of a wide array of modalities.  

For further information, please visit: www.pcibiotech.com                 
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies




NRG Therapeutics Announces Senior Appointments as it Advances NRG5051 Towards First-in-Human Clinical Studies

STEVENAGE, United Kingdom, Oct. 23, 2025 (GLOBE NEWSWIRE) — NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.

NRG has identified a novel regulator of the mitochondrial permeability transition pore (mPTP) which is essential for pore opening and amenable to small molecule inhibition. This breakthrough has enabled the company to develop a new class of small molecule mPTP inhibitors which are designed to penetrate the brain effectively when taken orally. First-in-human studies of its lead development candidate NRG5051 are on track to commence in early 2026.

At NRG, Sarah Almond will be responsible for preclinical translational biology and will support the clinical biomarker strategy; David Brocklebank will be responsible for clinical operations and will support delivery of the phase 1 and 2 clinical trials; and Kathryn Oliver will provide project management support for NRG’s clinical asset NRG5051 and preclinical pipeline.

The team expansion follows NRG’s recent £50m series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) in a syndicate of leading international life science venture investors that also included British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures alongside existing investors Omega Funds and Brandon Capital. The new funds provide runway for completion of a Phase 2 clinical proof of concept study of NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), while also generating meaningful clinical data in Parkinson’s patients through a Phase 1b study.

NRG Therapeutics’ co-founder and CEO Neil Miller said,
“I am delighted to welcome Sarah, David and Kathryn to the team. Their combined skills and expertise will enable us to efficiently progress #NRG5051 through first-in-human clinical trials and into a PoC in #ALS/#MND, and to lay the ground for development in other indications including #Parkinson’s. They join us at a pivotal time as we seek to demonstrate the therapeutic potential of NRG’s first-in-class #mPTP inhibitors as disease modifying medicines for neurodegenerative diseases.”

NRG operates a semi-virtual business model, with an in-house R&D leadership and operations team in Stevenage, UK complemented by the expertise of experienced drug-discovery outsourcing partners. These new appointments grow the team to 11 including the three founders.

New appointee bios

Sarah Almond – VP of Translational Biology – brings three decades of scientific experience gained in biotechs and big pharma with a focus on CNS drug discovery. She has a strong record of advancing small-molecule programs from early discovery through IND and into clinical development. Most recently she was Head of Pharmacology at Astellas ESM-UK and prior to that at Mission Therapeutics supporting its Parkinson’s disease project into Phase I, guiding translational strategy and biomarker development. Earlier career experience includes at Charles River Laboratories, Takeda, AstraZeneca, and Merck. She has an BSc in Cell Physiology and Pharmacology from the University of Leicester and a MSc in Pharmacology and Toxicology from the University of Hertfordshire.

David Brocklebank – Director of Clinical Operations – is a clinical operations specialist with 37 years’ industry experience across all stages of clinical development including senior roles in Clinical Operations and Project Management at Shire Pharmaceuticals, Kissei Pharma Europe, Mitsubishi Tanabe, Takeda and Ono Pharma UK. Most recently he was Director, Clinical Operations at Kynos Therapeutics and prior to that at Outpost Medicine. In his early career he was a pharmacist in the NHS. He has a BPharm degree in Pharmaceutical Chemistry (Pharmacy) from the University of Bradford and an MRPharmS in Hospital Pharmacy from the Royal Pharmaceutical Society.

Kathryn Oliver – Director of Project Management – brings 15 years’ experience in biotech drug discovery and development having transitioned from a career as a medicinal chemist into project management. Gained experience in biotech project management at Macomics and RxCelerate following a period in the NHS. She has scientific research experience in industry from roles at Cellzome, Cambridge Biotechnology and UCB Pharma. She has an BSc in Chemistry with Industry from the University of Sheffield.

Media enquiries (for NRG Therapeutics)
Sue Charles, Charles Consultants – +44 7968 726585 sue@charles-consultants.com

About NRG Therapeutics – https://www.nrgtherapeutics.com

NRG Therapeutics is a neuroscience drug discovery company building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson’s and amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND).

The company’s pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mPTP) through a novel mechanism of action. Inhibition of the mPTP has been shown to protect neurones, reduce neuroinflammation and improve motor function in pre-clinical disease models. Its lead asset, NRG5051, has completed IND-enabling studies and is on track to enter the clinic in early 2026.

Based at the Stevenage Bioscience Catalyst (SBC), UK, NRG Therapeutics is a private company with equity investment from Brandon Capital, British Business Bank, Criteria Bio Ventures, Dementia Discovery Fund, M Ventures, Novartis Venture Fund, Omega Funds and Parkinson’s UK. The company has also received awards from Innovate UK (Biomedical Catalyst Award), The Michael J. Fox Foundation, Target ALS and The ALS Association to support its innovative R&D programmes.

Follow us on LinkedIn.